Hicon (Sodium Iodide I-131) therapy coverage criteria
Customize your policy alerts
Sign up for Independent Health Policy M20200508035 alerts
Get alerted when Policy M20200508035 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria and coverage stance for a single administration of Hicon (radioactive iodide I-131) for treatment of hyperthyroidism and differentiated thyroid carcinoma across applicable Independent Health lines of business.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.